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Rheumatoid arthritis (RA) is a systemic autoimmune disease and its targeting of the joints indicates the presence of a candidate
autoantigen(s) in synovial joints. PatientswithRA show immune responses in their peripheral blood to proteoglycan (PG) aggrecan.
One of the most relevant animal models of RA appears to be proteoglycan-induced arthritis (PGIA), and CD4+ T cells seem to play
a crucial role in the initiation of the disease. In this review, the role of various T cell epitopes of aggrecan in the induction of
autoreactive T cell activation and arthritis is discussed. We pay special attention to two critically important arthritogenic epitopes,
5/4E8 and P135H, found in the G1 and G3 domains of PG aggrecan, respectively, in the induction of autoimmune arthritis. Finally,
results obtained with the recently developed PG-specific TCR transgenic mice system showed that altered T cell apoptosis, the
balance of activation, and apoptosis of autoreactive T cells are critical factors in the development of autoimmunity.
1. Structure and Function of the Cartilage
Proteoglycan (PG) Aggrecan Molecule
PGs are complex macromolecules composed of a protein
core to which glycosaminoglycan (GAG) and N-linked and
O-linked oligosaccharide side chains are attached. The PG
aggrecan (10–20% of the wet weight) provides a compressive
strength to the articular cartilage.There are twomajor classes
of PGs in articular cartilage: large aggregating PG mono-
mers or aggrecans (henceforth PG aggrecan) and small PGs
including decorin, biglycan, and fibromodulin [1]. They are
synthesized by chondrocytes and secreted into the extracel-
lular matrix, and their function is to maintain the fluid and
electrolyte balance in the articular cartilage [2]. Most of the
cartilage PG aggrecans are large molecules of high density
which bind to hyaluronan (hyaluronic acid, HA) to form
macromolecular aggregates [3–5].Thus, the PGmolecules do
not exist in isolation within the extracellular matrix, rather
they are present in aggregated form (PG aggregates). Each
aggregate is composed of a central filament of HA to which
up to 200 PG aggrecan molecules are bound, and each PG
aggrecan-HA interaction is stabilizedwith a third component
called link protein [6].
The core protein of PG aggrecan contains three globular
domains: two near the N-terminus (G1, which contains the
HA-binding region, and G2) and one at the C-terminus
(G3 domain) which contains epidermal growth factor-like,
complement regulatory, and lectin-binding subdomains [7]
(Figure 1). The G1 domain is composed of three functional
subdomains termed as A, B, and B󸀠, of which the B sub-
domain can bind to HA (Figure 1) [4, 6]. The G2 domain
also possesses two B-type subdomains, but none of them can
interact with HA, and, at present, their function is unknown.
TheG1 andG2 domains are separated by a short interglobular
domain (IGD), and the G2 and G3 domains are separated
by a long GAG-attachment region, which is rich in keratan
sulphate (KS) and chondroitin sulphate (CS) side chains
(Figure 1) [6].
The G3 domain resides at the carboxyl-terminus of
the core protein and contains a variety of distinct struc-
tural domains (Figure 1) [6, 7]. This domain contains
homology with the C-type lectin, but to date no distinct
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Figure 1: The schematic structure of PG aggrecan. The macromolecule consists of a central core protein to which hundreds of chondroitin
sulphate (CS) and keratin sulfate (KS) side chains are attached. Note that the N- and C-terminal G1 and G3 domains are “overrepresented”
in the figure for better visibility. The four most important T cell epitopes are indicated by black rectangles in the G1 and G3 domains. IGD:
interglobular domain, SCR: complement regulatory protein-like module, and CLD: C-type lectin-like domain. Two dominant arthritogenic
epitopes (5/4E8 and P135H), which are discussed in more detail in this work, are indicated.
carbohydrate binding has been identified. It has been shown
that PG aggrecan via this domain can interact with certain
matrix proteins such as fibrillin, fibulins, or tenascin. These
molecules can form a complex network. Therefore, a large
number of PG aggrecan molecules form huge aggregates via
its N-terminal G1 domain bound to HA and may interact
with other macromolecules via their C-terminal G3 domain.
In addition, the G3 domain is essential for normal post-
translational processing of the PG aggrecan core protein and
subsequent secretion [8].
PG molecules rarely exist in intact form in the PG aggre-
gates of the cartilage matrix, rather the PG aggrecan core
proteins are subjected to proteolytic degradation. In arthritic
diseases, cartilage undergoes irreversible destruction in
response to various catabolic stimuli. Under such conditions,
PG aggrecan molecules are known to be rapidly degraded
and released from the cartilage matrix, followed by the deg-
radation of matrix collagens. A number of matrix metallo-
proteinases (MMPs) and disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS4/5) are the most
dominant proteolytic enzymes which degrade PG aggrecan.
These proteinases can cleave core protein of PG aggrecan
at highly specific sites mostly located within the IGD [9–
11]. Cleavage of the core protein results in the loss of the
part of the PG aggrecan molecule bearing the KS- and CS-
attachment domains, while the G1 domain remains attached
to the HA filament and LP in the tissue. There are additional
cleavage sites of the core protein of PG aggrecan, which
contribute to the C-terminal truncation of PG aggrecan, the
loss of the GAG chains, and the loss of tissue function [12].
2. Immunogenicity of Cartilage Components
Cartilage is one of the few immune privileged tissues in the
body inwhich it is essentially avascular and therefore not sub-
jected to close “internal” immunological surveillance. When
it is degraded, however, unique antigenic molecules (neoepi-
topes) become exposed [15–17], released, and subsequently
recognized by the immune system [18]. Thus, articular com-
ponentsmay trigger andmaintain immune responses to these
antigens [19, 20].
Several autoantigens are described in RA, including a
variety of proteins that become citrullinated in diseased
joints. Humoral autoimmunity to citrullinated proteins in RA
has gained increasing attention in recent years [21]. Citrulli-
nation is a posttranslational protein modification, where the
amino acid arginine is converted to citrulline by peptidyl
arginine deiminase-4 (PAD-4) [22, 23]. The presence of anti-
citrullinated protein Abs (ACPA) is highly specific for RA;
ACPA are detected even in a higher proportion of patients
than RF (although not all patients are positive) [24–27].
ACPA positivity is now included in the 2010 RA classification
criteria [28].The spectrum of ACPA-reactive proteins identi-
fied in RA patients so far includes citrullinated filaggrin [29–
31], fibrinogen [32, 33], vimentin [34–37], type II collagen
[33, 38–42], 𝛼-enolase [33, 43, 44], and some viral antigens
[45–47].
An intriguing observation is that the appearance of ACPA
in serum predates the onset of the clinical symptoms of RA
[27, 48, 49]. An ACPA epitope mapping study found low
titers of Abs recognizing only one epitope several years before
disease onset, but both the epitope repertoire and the titers of
ACPA increased markedly 2–4 years prior to the diagnosis
of RA [49]. These observations clearly suggest that humoral
autoimmunity to citrullinated proteins arises and expands via
epitope spreading during the preclinical and clinical stages of
RA.
The immune attack on the joints could also be initiated
by a cross-reactive immune reaction in response to unrelated
antigens by the mechanism of “molecular mimicry.” The
net result of such autoimmune reactions is that cartilage is
degraded further and more autoantigens are released. This
may lead to a chronic, self-perpetuating inflammation in
genetically predisposed individuals who are prone to develop
these autoimmune reactions [50]. Although autoimmunity to
cartilage proteoglycans has been studied less intensively than
autoimmunity to type II collagen, cartilage PG (aggrecan) is
considered as causal/contributing factor in rheumatoid joint
disease [2, 13, 51, 51–58].
Patients with rheumatoid arthritis (RA) show cellular
immune responses in their peripheral blood to PG aggrecan
BioMed Research International 3
[2, 54]. The incidence of immune response to PG aggrecan
epitopes in patients with RA varied from 5 to 85%, depending
upon the study. Cellular immunity to proteoglycan has also
been described in patients with juvenile rheumatoid arthritis
[54], and immunoreactive fragments of PG aggrecan and
anti-PG antibodies have been demonstrated in the synovial
fluids of patients with RA [59]. All these studies suggest that
cartilage PG aggrecan may play an important role in the
development of autoimmunity against peripheral joints.
3. Rheumatoid Arthritis (RA) and Its
Experimental Animal Models
RA is one of the most frequent systemic autoimmune dis-
eases; it affects approximately 1% of the human population
with a female preponderance. Genetic factors play a signifi-
cant role in RA susceptibility. However, the concordance of
this disease in monozygotic twins is only 15%. It has been
therefore hypothesized that, while RA susceptibility is deter-
mined genetically, disease onset may depend on nongenetic
(i.e., environmental), epigenetic, or posttranslational events
[60].
Several lines of evidence indicate that the effector mech-
anism, which initially attacks small joints, is T cell driven.
As a result, an aggressive synovial pannus develops, which
destroys articular cartilage and bone, leading to massive
ankylosis and deformities of peripheral joints.Thedisease has
a progressive character, with the involvement of more and
more joints. Although RA is a systemic autoimmune disease,
it targets peripheral joints which suggests the presence of
candidate autoantigen(s) in synovial joints [2, 8, 61]. There
are numerous rodent models that simulate some or many of
the clinical, immunological, or histopathological features of
the disease. It has become a strong working hypothesis that
MHC and non-MHC genetic components share loci that are
common in various autoimmune diseases and in correspond-
ing animal models [62]. The most relevant animal models of
rheumatoid arthritis appear to be those induced by cartilage
matrix components such as PG aggrecan or type II collagen
[63–65]. The pathologic basis in both model systems appears
to be cross-reactive immune reactions: T cells and antibod-
ies raised against the immunizing heterogeneous (bovine,
human) cartilage antigens recognize and subsequently attack
the mouse’s own tissues (self) [66, 67].
4. PG (Aggrecan)-Induced Arthritis (PGIA)
Systemic immunization of genetically susceptible strains of
mice with human cartilage PG that has been depleted of
GAG side chains, that is, more or less degraded, leads to the
development of progressive polyarthritis [8, 63]. PGIA shows
many similarities to RA as indicated by findings of clinical
assessments, radiographic analyses, scintigraphic bone scans,
laboratory tests, and histopathologic studies of synovial joints
[8, 63].
PGIA was first described in the BALB/c strain [63], but
certain C3H colonies (e.g., C3H/HeJCr) were also found to be
susceptible to PGIA [68]. During the immunization protocol,
female mice are injected intraperitoneally with 100 𝜇g of car-
tilage PG aggrecan (measured as protein) in adjuvant (CFA/
IFA or DDA) three-times every third week. The initial clin-
ical manifestations of joint inflammation (swelling and red-
ness) appear after the third to fourth intraperitoneal injection
depending on the source of PG antigen, adjuvant, and
BALB/c or C3H colony used [4, 63, 66, 68–70]. Joint inflam-
mation starts as polyarticular synovitis in small peripheral
joints. During the early phase, lymphocytes and polymor-
phonuclear leukocytes invade the synovium.This is followed
by gross, “tumor-like” proliferation of synovial lining cells
and fibroblasts. Once an animal develops, arthritis repeated
“spontaneous” episodes of inflammation result in complete
destruction of the articular cartilage and erosion of the
subchondral bone, which leads to severe deformities of the
peripheral joints [63, 66, 69]. The disease is polygenic, has
a recessive inheritance, and major histocompatibility com-
plex (MHC) and non-MHC components are critical for the
development of arthritis [71–73].
PGIA in BALB/c mice is a T cell-dependent and
(auto)antibody/B cell-driven disease. Antibodies against
immunizing (human) PG aggrecan appear during the sec-
ond/third week of immunization. T cell response to PG
aggrecan is detectable approximately 5–7 weeks after the
first immunization, and along the course of the disease the
humoral and cellular immune responses slowly decline as the
disease becomes chronic and less active [63, 66, 69].
CD4+ T cells have been implicated in the development
of PGIA by observations that anti-CD4 mAb treatment
prevents arthritis and that the transfer of the disease requires
T cells from arthritic animals [74, 75]. BALB/c mice are
genetically predisposed to a Th2-type immune response;
however, immunization of these mice with PG aggrecan
induces a higher ratio of IFN-𝛾 to IL-4, indicating that PGIA
is a Th1-type disease and immunization with PG aggrecan in
either Freund’s adjuvant or DDA is a sufficient Th1 stimulus
to overcome the genetic inclination toward development of a
Th2-type response [76].
Treatment withTh2 cytokines before the onset of arthritis
prevents the development of arthritis, indicating that a switch
from a Th1-type response to a Th2-type response is critical
for the control of joint inflammation associated with arthritis
[76]. Moreover, in PGIA, neutralization of IFN-𝛾 inhibits
arthritis and IFN-𝛾−/− mice develop arthritis with delayed
onset and reduced severity in comparison to wild-type (WT)
mice. These findings indicate that IFN-𝛾 is an important
proinflammatory cytokine promoting disease severity in
PGIA [76].
IL-17 has emerged as an important proinflammatory
T cell cytokine in several models of arthritis [77–79]. In
line with this, significant amount of IL-17 production was
detected in the early (initiation) phase of PGIA in normal
BALB/c mice [80]. IL-17 production by isolated peritoneal-
(from the site of PG immunization) or spleen cells was
detected already after the first and second antigen (PG)
challenges, before the development of the clinical signs of
arthritis, showing that the Th17 cells were generated both
locally and systemically [80]. Based on these results we pro-
posed a pathogenic role for IL-17 in PGIA initiation [80].
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However, contrary to the dependence on IL-17 described in
othermodels of arthritis (e.g., collagen-induced arthritis), IL-
17-deficientmice developedPGIA similar toWTanimals [81].
This contradiction was resolved when IL-17/IFN𝛾 double
knockout mice were tested for PGIA [82]. Results from this
Th1/Th17 deficient system have clearly shown that the IL-17
“independency,” found earlier, was due to amore robust IFN-
𝛾 response in the absence of IL-17 which compensated the
effect of IL-17-deficiency [82]. When IFN-𝛾 was absent too,
the effect of IL-17 could be observed more clearly in PGIA
[82]. Taken together, these data suggest that PGIA is a dis-
ease with Th1 dominance; however, contribution from IL-
17 (similar to human RA), especially in the initiation of the
autoimmune reactions, has to be considered too [80].
5. Collagen-Induced Arthritis (CIA)
Besides PGIA, collagen-induced arthritis (CIA) is the other
widely used experimental autoimmune arthritis model sys-
tem. CIA was originally elicited in rats following a single
intradermal injection of type II collagen (CII) emulsified in
Freund’s adjuvant [64]. Further studies demonstrated that a
similar pathology could also be induced in primates [83] and
in susceptible strains of mice [65]. CIA can be induced using
native autologous or heterologous CII and is specific to CII,
since immunizationwith type I or III collagen failed to induce
disease [64, 65]. While either incomplete (IFA) or complete
Freund’s adjuvant (CFA) can be used to trigger CIA in rats,
the induction of disease in mice generally requires the pres-
ence of heat-killed mycobacterium tuberculosis in CFA [65].
ImmunizationwithCII/CFA results in a rapid and severe pol-
yarthritis of the peripheral articular joints which first appears
around 3-4 weeks after antigen challenge and becomes pro-
gressively worse for approximately 2–4 weeks before slowly
waning. Whilst the pathology is similar when CIA is induced
with either autologous or heterologous CII, the nature of
the disease differs; autologous CII induces a more chronic
disease with a delayed onset and reduced penetrance [84, 85].
In both cases the histopathology of inflammatory arthritis
resembles human rheumatoid arthritis (RA). Like RA, CIA is
characterized by the presence of fibrin deposition, hyperpla-
sia of synovial cells, periosteal bone formation, mononuclear
infiltrates, pannus formation, and eventual ankylosis of one
or more articular joints [64].
While the precise mechanisms by which immunization
with heterologous or autologousCII in CFA leads to a chronic
arthritis in susceptible mice are not known, there are consid-
erable data to implicate CII-reactive CD4+ T cells as the pri-
mary mediators of disease induction and complement-fixing
anti-CII autoantibody production by B cells as the major
immune mechanism leading to the localized chronic inflam-
matory response [86]. CIA is classified as aTh1-mediated dis-
ease based on the abundant IFN-𝛾 production [87]. However
the role of IFN-𝛾 in CIA is more complex. Complete elim-
ination of IFN-𝛾 or IFN-𝛾 receptor signaling led to the
exacerbation of disease [88, 89]. On the other hand, neutral-
ization of IFN-𝛾 at an early stage of disease inhibited arthritis
[90]. The ability of IFN-𝛾 to suppress Th17 cells appears to
account for augmented disease in IFN-𝛾−/− or IFN-𝛾 receptor
deficient mice in CIA, as inhibition of IL-17 with neutral-
izing antibodies suppressed arthritis [91]. Autoreactivity to
cartilage CII in human RA patients, although not a defining
feature of the disease, has been clearly demonstrated [92, 93].
6. T Cell Epitopes in Cartilage PG Aggrecan
Previously, in an epitope mapping study using a total of
143 synthetic peptides containing predicted T cell epitopes,
27 peptide sequences were identified wich induced T cell
responses in PG-immunized BALB/c mice [4]. An epitope
hierarchy, accounting for the different effector functions of
PG (aggrecan)-specific T cells, and determinant spreading,
has been established. Some of the T cell epitopes were full T
cell activators, whereas a number of subdominant and cryptic
epitopes proved to be partial activators in vitro, inducing
either cytokine secretion or T cell proliferation, but not both
[4]. A few T cell epitopes of the core protein of cartilage PG
aggrecanwere clearly recognized byT cells in PG-immunized
arthritic animals, but the corresponding peptides did not
induce T cell responses when injected into naive BALB/c
mice; thus these T cell epitopes were designated as “condi-
tionally immunogenic” [4].
Importantly, T cell responses to only four epitopes were
clearly associated with arthritis induction in mice (hence-
forth “arthritogenic” epitopes) [94]. Out of these four epi-
topes, three were found in theG1 and one in theG3 domain of
PG aggrecan (Figure 1) underlining the importance of these
regions in the induction of arthritis. More specifically, P49–
63 and P70–84 lie in the A loop, whereas P155–169 lies in the
B loop of the G1 domain and P2373–2387 in the G3 domain
of PG (Figure 1) [94]. The positions of arthritogenic T cell
epitopes clearly show that the two terminal regions of the
large PG molecule are involved in the induction of T cell
response, most likely because they are more easily accessible
to the immune system than the inner regions which are
“covered” with KS and CS side chains (Figure 1). Two T cell
hybridomas (5/4E8 and P135H), established earlier from the
T cells of mice with PGIA, also recognized two of the above-
mentioned arthritogenic epitopes: P70–84 and P2373–2387,
respectively [95, 96]. Injection of either unprimed or peptide-
primed 5/4E8 or P135H hybridomas into naive BALB/c
or BALB/cSCID mice, respectively, induced arthritis. These
observations underline the importance of the G1 and G3
domains in PG in the generation of arthritogenic T cells.
7. The Hypothetic Role of T Cells Specific for
a ‘‘Shared Epitope-Like’’ Sequence in
the G3 Domain of PG, in the Initiation of
Autoimmune Inflammation in
PG-Induced Arthritis
The G3 domain resides at the carboxyl-terminus of the core
protein of PG aggrecan and is structurally distinct from the
G1 and G2 domains. It contains an EGF module (EGF1),
a calcium-binding EGFmodule (EGF2), a C-type lectinmod-
ule (CLD), and a complement regulatory protein-likemodule
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(SCR) (Figure 1). The C-type lectin module is constitutively
expressed and mediates binding to other extracellular matrix
molecules, for example, tenascin-R, fibulin-1, fibulin-2, and
fibrillin-1 [8]. The subdomains (modules) of the G3 domain
are subjected to alternative splicing. The expression of the
SCR module is variable, but this module is usually present in
humans regardless of the age. The EGF1 and EGF2 modules
are expressed to a lower extent (25–28% and 5–8%, resp.,
in humans). The EGF2 module (a splice variant) is highly
conserved and uniformly expressed at low levels in several
species, whereas the less conserved EGF1module is expressed
at different degrees due to also a splicing mechanism [7, 97].
These differences and the alternative splicing of the EGF-like
repeatsmay reflect different functions for the EGF1 and EGF2
modules in different species. Expression of the EGF modules
could constitute a mechanism for feedback regulation of
differentiation and proliferation of chondrocytes. In addition,
alternatively spliced modules of the G3 domain could affect
GAG substitution of PG and transport through the secretory
pathway.The alternative splicing of the flankingEGF and SCR
modules could also have a regulatory function bymodulating
the C-type lectin-mediated interactions [8]. The loss of PG
aggrecan is amajor feature of cartilage degradation associated
with arthritis [98]. There is an age-related loss of the G3
domain of PG, and 92% of the G3 domain is lost as part of the
normal turnover of the PGs, whereas the rest of the molecule
bound to HA is retained in the cartilage [99].
As described in the previous section, while most of
the T cell epitopes are located within the poorly glycosyl-
ated globular G1 domain [94], one of the epitopes is present
in the G3 domain at the C-terminus of the human PG.
Hyper-immunization of BALB/c mice, with a synthetic pep-
tide (p135H) representing a segment of the human PG G3
sequence (2373TTYKRRLQKRSSRHP) followed by the injec-
tion of a single dose of PG, induced progressive polyarthritis
[100]. Using an adoptive transfer system, p135H peptide-
stimulated lymphocytes and T cell hybridomas from peptide
p135H-primed BALB/c mice were also capable of inducing
arthritis in SCID mice “presensitized” with a single injection
of PG aggrecan, with a relatively high incidence and severity
score [100].
A special feature of this T cell epitope is that the p135H
contains a conserved amino acid sequence QKRSS, which
shows striking similarity to the “shared epitope” (SE) of
QKRAA amino acid sequence. This SE is located in the
third hypervariable region of certain HLA alleles associated
with RA [101]. HLA-derived peptides encompassing the SE
sequence can randomly select T cells that bind the self-
derived peptide at low avidity. Later in life, these previously
quiescentQKRAA-specific T cells can be activated by binding
with high avidity an exogenous peptide containing the SE
[101]. Interestingly, proteins in common human pathogens,
such asEscherichia coli (DnaJ heat-shock protein),Lactobacil-
lus lactis, Brucella ovis (DnaJ heat-shock protein), Epstein-
Barr virus (gp110 protein), and human JC polyomavirus
(capsid protein VP3) have been identified wich express the
SE in the context of highly immunogenic proteins, and
immune responses to several of these antigens have been
evaluated inRApatients (Figure 2) [102–105].These sequence
data suggest that immunologic cross-reactivity might exist
between certain RA-associated HLA alleles, the above-
mentioned immunogenic proteins of human pathogens and
the p135H peptide sequence—a T cell epitope of human
cartilage PG aggrecan. Intermittent exposure of the immune
system to these bacterial or viral antigens at mucosal surfaces
might lead to the activation of resting QKRAA-specific
T cells and then the T cell activation is perpetuated by
encounters with peptides of self-origin, encompassing the SE
sequence (Figure 2). It seems to be an attractive hypothesis
that the sequence of p135H in human cartilage PG aggrecan
can serve as an analog of SE, and it may be responsible for the
joint-specific homing ofQKRAA-reactive T lymphocytes and
then be involved in the initiation of the autoimmune process
in RA (Figure 2) [101].
As described above, in the process of aging, the vast
majority of the G3 domain is lost as the part of the normal
turnover of cartilage PG aggrecan [99], whereas the rest of
the molecule, including the G1 domain which is bound to
hyaluronan, is retained in the cartilage. The C-terminal tail
of PG is cleaved first, and two tandem “boxes” (RRXXK and
RXXR) of the consensus sequences have been demonstrated
to be involved in the earliest cleavage [6]. Interestingly, both
cleavage sites described are located within p135H peptide
sequence (TTYKRRXXKRXXRHP). Therefore, a significant
amount of p135H might be released from articular cartilage
due to normal turnover or due to an enhanced proteolytic
processing of the G3 domain (e.g., in inflammation or in
cartilage injury) and then be exposed to the immune system
in the joints (Figure 2). We might also suggest that this C-
terminal part of the G3 domain plays a role in the initial acti-
vation of T cells and, later, the rest of the molecule, especially
the G1 domain, becomes the main target. This process can be
interpreted as epitope spreading, that is, in the course of the
autoimmune inflammation when neo-epitopes are generated
(e.g., by citrullination of other parts of the molecule or by
enhanced proteolytic activity), which subsequently become
additional targets for the autoimmune response (Figure 2).
Unlike T cells, which react with epitopes in the G1 and
G3 domains of PG aggrecan, B cell epitopes are mostly found
in the CS attachment region of the molecule (Figure 1) [4].
Partial deglycosilation of aggrecan is required for a successful
induction of PGIA, because the remaining CS “stab-clusters”
provoke a strong antibody response [4]. Besides the age-
related loss of the G3 domain, the partial loss of CS side
chains is also a common change in PG aggrecan, leading to
the “uncovering” of important B cell epitopes. Reactive B
cells have strong antigen presenting capacity and thus might
contribute to the initial activation of T cells (Figure 2) [4, 106].
Activated T cells, in turn, help plasma cell differentiation
leading, eventually, to the production of aggrecan-specific
antibodies (Figure 2) [106].
8. The G1 Domain
TheG1 domain contains an immunoglobulin-like A loop and
HA-binding B and B󸀠 loops (Figure 1) [94, 107]. As men-
tioned above, three dominant/arthritogenic and four sub-
dominant epitopes are located in the G1 domain and only a
few cryptic or subdominant epitopes are located in the other
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Figure 2: Potential role of the P135 epitope found in the G3 domain of PG aggrecan in the development of arthritis. Importantly, this epitope
shares a significant sequence homology with the HLA-DRB1 “shared epitope” sequence (QKRSS in p135 versus QKRAA inHLA). Age-related
release of theG3 domain of PG aggrecan could lead to the activation and differentiation of autoreactive T cells. T cell tolerance could be broken
by several factors including neoepitope formation (e.g., citrullination) or molecular mimicry mechanisms (for more details see Section 6).
Activated P135-specific T cells could “home” into the joints, where further activation would lead to cytokine release and the activation of
B cells and macrophages. The initiation of the joint inflammation could perpetuate PG aggrecan degradation; the proteolysis and increased
citrullination could pave the way for “epitope spreading.” The involvement of the G1 domain contributes to the activation of even more
autoreactive T cells taking the autoimmune attack of the joints into a final irreversible stage.
regions of the PG molecule. Thus, only <0.02% of the com-
plete molecular mass, or <15% of the core protein, drives
the arthritogenic response to PG in genetically susceptible
BALB/c mice.
For the further characterization of T cell epitopes recog-
nized in the PG molecule, a PG (aggrecan)-specific V𝛽4+/
V𝛼1+ Th1 hybridoma (5/4E8) was isolated from mice with
PGIA. This CD3+/CD4+ T cell hybridoma induced inflam-
matory processes in the joints when injected intravenously
into naive irradiated BALB/c mice. I-Ad restricted recogni-
tion of PG induced IL-2 and IFN-𝛾 secretion and the
expression of CD44, CD28 and LFA-1 [95, 108]. The clinical
symptoms and histopathological features of this 5/4E8 T
cell hybridoma-induced arthritis was very similar to that
described in transfer experiments using lymphocytes from
arthritic animals [74, 109], but the onset of arthritis was earlier
and the incidence ranged between 45 and 90% [95].The 5/4E8
epitope (70ATEGRVRVNSAYQDK84; the core sequence is
underlined) is located on the G1 domain of human PG
molecule (Figure 1) [4] and has been identified as a dominant
and probably the most arthritogenic T cell epitope of PG in
the genetically susceptible BALB/c strain [94, 96]. A peptide
fragment of the G1 domain of PG aggrecan, containing the
5/4E8 epitope, was able to activate T cells derived from
human patients with RA [56]. Most recently, two indepen-
dent laboratories have reported that a citrullinated version
of the 5/4E8 epitope-containing aggrecan peptide VVLLV-
ATEGR/CitVRVNSAYQDK (5/4E8 sequence bold-faced in
italics and arginine/citrulline [R/Cit] substitution under-
lined) induced substantial cytokine (IL-17, IL-22, IL-6, TNF𝛼,
and IFN𝛾) production by T cells from the majority of RA
patients [58, 110]. RA T cells responded poorly to the native
(noncitrullinated) peptide in both studies, and T cells from
healthy subjects did not respond [58] or responded only to
the citrullinated peptide by producing IL-6 [110]. Although
the majority of RA patients tested were ACPA+ (anti-CCP+),
T cell response to the citrullinated peptide was also noted in
some ACPA− patients [58, 110]. These results suggested that
the 5/4E8 epitope (either native or citrullinated form) plays a
crucial role in PGIA and possibly involved in RA.
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The importance of the G1 domain in the development of
autoimmunity is clearly shown in a recent modification of
the PGIAmodel; immunizationwith the recombinant human
G1 (rhG1) domain could also trigger autoimmune arthritis
(henceforth G1 domain-induced arthritis “GIA” model) in
BALB/c mice [111]. The clinical phenotype, histopathological
abnormalities, and laboratory test results in the GIA model
were very similar to those described in “parental” PGIA, but
side-by-side experiments showed that mice with GIA devel-
oped arthritis more uniformly and with higher overall
inflammation scores than those with PGIA. The incidence of
arthritis reached 95–100% in both models, although disease
severitywas higher in theGIA than in the PGIAmodel. T cells
from mice with GIA produced more IL-2 and were activated
on a higher level upon in vitro stimulation with rhG1 than
with PG; likewise, T cells from mice with PGIA responded
more robustly to stimulation with PG than with rhG1. Auto-
antibodies against self (mouse)-PG were produced in same
amounts in both PGIA and GIA. When disease-associated
cytokines and antibodies were compared, higher serum levels
of IL-1𝛽, IL-17, and IgG-type RF and a higher IgG2a : IgG1
ratio of antimouse PG autoantibodies, were detected in GIA,
but higher quantities of anti-CCP antibodies (ACPA) were
measured in the PGIA model. PGIA is known as a Th1-type
of the disease with a strong IFN-𝛾 dominance [82] associated
with significant IL-17 production [80]. A more pronounced
production of IL-17 was found in GIA suggesting that the
latter disease is rather a mixed Th1/Th17-mediated form. The
detected differences between the IL-17 and IFN-𝛾 production
could contribute to the more severe clinical symptoms of
arthritis in mice with GIA. Because the two models (PGIA
andGIA) could be distinguished on the basis of “RA-specific”
serologic markers (RF and ACPA), they may represent two
subtypes of seropositive RA [111].
9. T Cell Receptor (TCR) Signaling
and Apoptosis in Arthritis
So far, we have reviewed the most important T cell epitopes
present in the PG aggrecanmolecule, which could contribute
to the induction of autoimmune T cell activation and differ-
entiation in animal models and perhaps in RA. Importantly,
T cell tolerance towards self-antigens ismaintained by several
parallel mechanisms. Thymic negative selection resulting
in “central” tolerance is completed by peripheral tolerance
mechanisms including regulatory T cells, suppressive cyto-
kines, and inhibitory costimulatory signals. When any of
these mechanisms of tolerance is broken by internal or exter-
nal factors, autoreactive T cells may accumulate and pave the
way to autoimmune inflammatory processes.
An important step to activate such events is the recog-
nition of peptides bound to MHC molecules of antigen pre-
senting cells (APCs), which initiates a cascade of intracellular
signaling events in T cells. TCR signaling proceeds through
a number of well-known steps, including the activation of
Lck by CD45 and then the phosphorylation of ZAP-70, fol-
lowed by phosphorylation of LAT, SLP-76, and PLC𝛾 [112].
Later, the intracellular Ca2+ level rises, the MAPK cascade
is also activated, and the net effect is the activation of some
important transcription factors (AP-1, NF-AT, and NF-𝜅B).
As a consequence, activated T cells will enter the cell cycle,
produce cytokines, and differentiate. Normally, the activation
of T cells is limited by activation-induced cell death (AICD).
However, several lines of evidence show that dysregulation of
TCR signaling, activation, and apoptosis could play a role in
the pathogenesis of RA.
TCR transgenic (TCR-Tg) mice were also generated, in
which mice more than 90% of the CD4+ T cells expressed
the V𝛼1.1 and V𝛽4 chains recognizing dominant and possibly
most arthritogenic “5/4E8” T cell epitope (see above in
Section 7) [4, 113]. Importantly, this transgenic mouse offered
an excellent tool to study the above-mentionedTCR signaling
events in the context of PGIA.
Two transgenic (TCR-TgA and TCR-TgB) lines were gen-
erated from different pronuclear injections using the same
construct [114]. Transgene-positive founders were back-
crossed into the BALB/c background. Both TCR-TgA and
TCR-TgB strains possess the same epitope (5/4E8)-specific
TCR expressing CD4+ T cell repertoire. However, CD4+ T
cells of TCR-TgBmice expressed twice as much TCR on their
surface when compared to the TCR-TgA line [114]. Con-
tradictory to the level of TCR expression (higher in TCR-
TgB mice), TCR-TgA mice developed earlier a very severe
arthritis when immunized with either PG or rhG1 compared
to theWTBALB/c controls [114], and, surprisingly, TCR-TgB
mice exhibited delayed onset and less severe arthritis than
TCR-TgA mice [114]. When the underlying mechanisms of
these profound differences were investigated, elevated serum
levels of anti-G1 antibodies were found in the TCR-TgA
strain before the first visible signs of inflammation appeared
[114]. Concordant with the higher serum levels of G1-specific
antibodies, a higher number of antibody producing B cells
was found in TCR-TgAmice [114]. Secretion of these antigen-
specific antibodies is not only part of the B cell function,
because these B cells are very important as APCs in PGIA
[4, 106, 115, 116] and probably in GIA as well (Figure 3(a)).
The higher number of B cells in TCR-TgAmice could present
antigen to T cells more effectively and led to a more extensive
T cell activation (Figure 3(a)). In turn, activated CD4+ T cells
play key role in the initiation of PGIA and GIA (Figure 3(a))
[80, 111]. Furthermore, fine phenotypic analysis of TCR-TgB
mice revealed a lower percentage of ICOShigh CD4+ T cells,
probably follicular T helper cells (Tfh), which are critical in
systemic autoimmunity by supporting autoreactive B cells
[117]. ICOS has been shown to be indispensable in collagen-
induced and K/BxN arthritis models [118–120], and certain
ICOS polymorphisms are associated with RA [121]. The
importance of costimulatory signals in RA (Figure 3(a)) is
also supported by the successful clinical use of Abatacept, a
recombinant fusion protein of CTLA-4 [122].
As described above, the differential expression level of the
TCR in the TCR-TgA and -TgBmice was contrary to the clin-
ical phenotype; the higher TCR expression led to less severe
arthritis [114]. In the background, a significantly stronger
TCR signal (higher phosphorylation levels of key signaling
molecules, e.g., ZAP-70 and p38) was found in the TCR-TgB
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Figure 3: The balance of T cell activation and apoptosis regulates the development of autoimmune arthritis in PGIA. (a) The interaction
between APCs and T cells determines T cell activation. TCR signal strength is regulated by costimulation and TCR expression. When the
activation signal is optimal, T cell activation will lead to the autoimmune attack of joints. (b) Relation between the strength of the TCR signal
and arthritis severity in the PG-specific TcR-Tg mice. The two mouse colonies (TCR-TgA and TCR-TgB) were described in [13]. The use of
homo- (+/+) or heterozygous (+/−) TCR-Tg mice allowed us to further refine our TCR signal strength studies in PGIA. Activation (red line)
or apoptosis (blue line) of T cells is regulated by TCR signal strength.When the activation exceeds apoptosis, the autoreactive cells accumulate
and arthritis develops (grey area). When apoptosis overrides activation the autoreactive T cells are eliminated and arthritis does not develop.
Spontaneous arthritis (dark grey zone) was only observed in homozygous TCR-TgA mice [14]; thus, at least from the T cell signaling side, a
very narrow “window” exists when T cell activation is optimal and is over the apoptosis.
mice, which expressed twice as much TCR on the surface
of CD4+ T cells when compared to the TCR-TgA line [114].
The higher TCR expression and stronger T cell signaling
provoked extensive apoptosis of CD4+ autoreactive T cells
during immunization with an antigen (rhG1) containing the
5/4E8 epitope. This might lead to the elimination of acti-
vated arthritogenic T cells and decreased arthritis severity
(Figure 3(b)) [114]. All of these apoptosis studies have been
performed using the AnnexinV/PI staining and analyzed
by flow cytometry. Further studies would be needed to
determine which apoptosis pathways are activated.
Altered T cell apoptosis has been found as a critical factor
in the development of autoimmune arthritis by others as well
[14, 123, 124]. Results obtained with the PG-specific TCR-Tg
mice showed that TCR signal strength controls the onset and
severity of arthritis by regulating the activation and apoptosis
of T cells (Figure 3(b)). An optimal TCR signal leads to a
strong activation of T cells which then induce arthritis very
efficiently leading to a “superarthritic” phenotype, while an
extremely “strong” TCR signal generated only a milder form
of arthritis (Figure 3(b)). Thus, the balance of activation and
apoptosis of autoreactive T cells (i.e., arthritis severity) seems
to be controlled by TCR signal strength (Figure 3(b)).
In aging homozygous TCR TgAmice, arthritis developed
spontaneously, too [14]. Although the clinical picture was
somewhat different from the PGIA, we hypothesize that this
can also be explained by TCR signal strength as described
above (Figure 3(b)). A low threshold, continuous activation
of autoreactive T cells associated with impaired apoptosis
may result in the development of spontaneous arthritis [14]
(Figure 3(b)). Spontaneous arthritis never developed in the
TCR TgB strain, most likely to the stronger TCR signal,
which led to the continuous elimination of the autoreactive T
cells (Figure 3(b)).This, again, supports our hypothesis about
the regulatory role of TCR signal strength in autoimmune
arthritis (Figure 3).
10. Concluding Remarks
Herein we summarized our current knowledge of PG immu-
nity mostly based on the results of PGIA model with special
attention to T cell activation. This mouse arthritis model has
provided profound insight not only to the most important T
cell epitopes of PG aggrecan but also to their role inT cell acti-
vation and apoptosis. Based on data from recently developed
TCR-Tg mice, a new hypothetic model could be established
showing the importance of TCR signal strength in the
pathomechanism of arthritis. Although PG aggrecan is only
one of the potential autoantigens in cartilage or joint, which
can drive the autoimmune attack in RA, there is increasing
evidence that this tissue-restricted cartilage macromolecule
(PG aggrecan) may also be a potential autoantigen in RA and
some analogies can be found in the mechanism of PGIA and
RA.
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